Table 2.

Results of univariable analyses of risk factors for 5-year tumor recurrence

Factors	Hazard ratio	95 % confidence interval	P
Male recipient gender	0.84	0.39–1.83	0.663
Recipient age	0.97	0.93–0.99	0.034
MELD	0.99	0.92–1.07	0.814
HCV infection	1.00	0.47–2.13	0.998
HBV infection	1.41	0.69–2.85	0.343
Within Milan criteria	0.22	0.10–0.48	<0.001
Within UCSF criteria	0.25	0.12–0.50	<0.001
Within up-to-7 criteria	0.17	0.08–0.36	<0.001
Number of tumors	1.31	1.18–1.44	<0.001
Size of the largest tumor	1.02	1.01–1.04	0.001
Total tumor volume	1.01	1.01–1.02	<0.001
Pre-transplant AFP >100 ng/ml	4.30	2.05–9.00	<0.001
Poor tumor differentiation	2.90	1.25–6.73	0.013
Microvascular invasion	2.23	1.09–4.57	0.029
Neoadjuvant treatment	1.36	0.67–2.76	0.393
Total ischemic time	1.15	0.94–1.39	0.172
Intraoperative PRBC transfusions	1.00	0.93–1.07	0.986
Intraoperative FFP transfusions	0.98	0.90–1.06	0.626

Hazard ratios were given per: 1 year increase for recipient age; 1 point increase for model for end-stage liver disease; 1 tumor more for number of tumors; 1 mm increase for the size of the largest tumor; 10 cm³ increase for total tumor volume; 1 log_e increase for alpha-fetoprotein; 1 h increase for total ischemic time; and 1 unit increase for packed red blood cells and fresh frozen plasma transfusions

MELD model for end-stage liver disease; HCV hepatitis C virus; HBV hepatitis B virus; UCSF University of California, San Francisco; AFP alpha-fetoprotein; PRBC packed red blood cells; FFP fresh frozen plasma